TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35482910
Drug: TETA-2HCl treatment
Normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TETA-2HCl treatment
Study: 35484319
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose of 15 mg/kg every 2 weeks for patients aged < 12 years or weighing < 40 kg
Study: 35484319
Drug: Recommended adult
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended adult flat dose of 800 mg every 2 weeks for patients aged ≥ 12 years and weighing ≥ 40 kg
Study: 35484649
Drug: Itolizumab (anti-CD6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itolizumab (anti-CD6 monoclonal antibody)
Study: 35484817
Drug: Twice-daily enoxaparin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily enoxaparin (initial dose: 0.5mg/kg per dose; max: 60mg; target anti-Xa activity: 0.20-0.49IU/mL)
Study: 35486436
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (control)
Study: 35486475
Drug: Midostaurin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin plus intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and 1-year midostaurin maintenance therapy
Study: 35486475
Drug: Midostaurin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin plus intensive chemotherapy
Study: 35486638
Drug: Lurbinectedin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks
Study: 35487733
Drug: Polypharmacy (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (defined as the concomitant use of five or more medications, excluding vitamins or dietary supplements)
Study: 35487814
Drug: 9-valent human
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent human papillomavirus vaccine (9vHPV)
Study: 35487845
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (SC trastuzumab) administered every 3 weeks for 18 cycles as adjuvant therapy
Study: 35487845
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab with no chemotherapy
Study: 35487845
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab with concurrent chemotherapy
Study: 35487845
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab with sequential chemotherapy
Study: 35487894
Drug: Wheelchair-modified ergometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheelchair-modified ergometer rowing exercise (REMW), 3 times weekly for up to 30 minutes per session
Study: 35488337
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids plus long-acting beta agonists
Study: 35488900
Drug: Glasdegib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib (100 mg once daily) + azacitidine
Study: 35489133
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug use
Study: 35489233
Drug: Regorafenib (REGO)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib (REGO) 160 mg/day for 21 days of a 28-day cycle
Study: 35489377
Drug: Dolutegravir dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir dispersible tablets (5 mg)
Study: 35491511
Drug: STAR-OX40 T-cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAR-OX40 T-cell therapy
Study: 35491519
Drug: Low-dose glibenclamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glibenclamide
Study: 35492329
Drug: Low Fat-Free
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Fat-Free Muscle Index (L-FFMI)
Study: 35492329
Drug: Large Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large Total Cross-Sectional Spontaneous Portosystemic Shunt Area (L-TSA)
Study: 35492329
Drug: Simultaneous presence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous presence of L-FFMI and L-TSA
Study: 35492329
Drug: L-FFMI
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-FFMI
Study: 35492329
Drug: L-TSA
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TSA
Study: 35492873
Drug: AXL targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXL targeting intervention, details on dosage and duration not available
Study: 35492875
Drug: CCL18 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCL18 treatment
Study: 35493124
Drug: Bamlanivimab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab (700 mg) and Etesevimab (1400 mg)
Study: 35493516
Drug: PF-06671008 (1.5-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06671008 (1.5-400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle
Study: 35493739
Drug: Microbial samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial samples from the oral cavity, sputum, and ileum of patients with CD
Study: 35493739
Drug: Oral cavity
Normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cavity and sputum microbiota
Study: 35493739
Drug: Microbiota composition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota composition in oral cavity and sputum
Study: 35493739
Drug: Microbiota architecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota architecture in oral cavity, sputum, and ileum
Study: 35496758
Drug: rHIgM22 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHIgM22 (0.5 or 2.0 mg/kg)
Study: 35497778
Drug: Clazakizumab 25
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab 25 mg subcutaneously (s.c.) monthly for 12 months
Study: 35497778
Drug: Clazakizumab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab treatment
Study: 35498381
Drug: Camrelizumab plus
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab plus low-dose apatinib
Study: 35499083
Drug: Hymecromone 1200
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 1200 mg/d
Study: 35499083
Drug: Hymecromone 2400
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 2400 mg/d
Study: 35499083
Drug: Hymecromone 3600
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 3600 mg/d
Study: 35499083
Drug: Hymecromone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone (all doses combined)
Study: 35499104
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg/day, increased to 20 mg/day after 1 week
Study: 35499706
Drug: IL-6 treatment
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 treatment on bystander COLO205 cells
Study: 35499827
Drug: Nonoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative management with antibiotics
Study: 35500016
Drug: Bexmarilimab (humanized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexmarilimab (humanized IgG4 antibody against Clever-1)
Study: 35500404
Drug: E7389-LF 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF 2.0 mg/m
Study: 35500404
Drug: E7389-LF 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF 2.0 mg/m with prophylactic pegfilgrastim
Study: 35501102
Drug: Plasma (P)-myoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma (P)-myoglobin and P-creatine phosphokinase analyzed at 6-hourly intervals after admission for 48 hours and after surgical fixation or fasciotomy for 24 hours.
Study: 35501309
Drug: (2R,6R)-HNK (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2R,6R)-HNK (10 mg/kg)
Study: 35501592
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg single oral dose
Study: 35503163
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg qw
Study: 35503163
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg q2w
Study: 35503163
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg qw or q2w
Study: 35503244
Drug: Sunnyside (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunnyside (6-week cognitive behavioral therapy-based web-based intervention)
Study: 35503244
Drug: Sunnyside Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunnyside Plus (6-week cognitive behavioral therapy-based web-based intervention with additional education and support for human milk feeding)
Study: 35505238
Drug: Intradermal reaction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal reaction (IDR) test in likely insulin allergy patients
Study: 35505238
Drug: Intradermal reaction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal reaction (IDR) test in possible insulin allergy patients
Study: 35505238
Drug: Intradermal reaction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal reaction (IDR) test in unlikely insulin allergy patients
Study: 35505238
Drug: Intradermal reaction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal reaction (IDR) test in case-control study
Study: 35505238
Drug: Skin prick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin prick and serum anti-insulin IgE tests in case-control study
Study: 35506108
Drug: GSK2586881 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586881 (0.1, 0.2, 0.4, or 0.8 mg/kg, single intravenous dose)
Study: 35506190
Drug: Daily mango
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mango consumption, dosage not specified, duration not specified
Study: 35507014
Drug: Doxorubicin-cyclophosphamide-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-cyclophosphamide-based neoadjuvant therapy
Study: 35507355
Drug: Standard 2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2-dose SARS-CoV-2 vaccination regimen
Study: 35507355
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of SARS-CoV-2 vaccine
Study: 35507396
Drug: CDSS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDSS intervention in treatment practices
Study: 35507396
Drug: CDSS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDSS intervention in treatment practices (subgroup analysis)
Study: 35507739
Drug: Maralixibat 266
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat 266 μg/kg orally, once daily, from baseline to Week 72, with twice-daily dosing permitted from Week 72.
Study: 35507774
Drug: Placebo cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cooling patch intervention
Study: 35507774
Drug: Placebo cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cooling patch intervention for DFU
Study: 35508346
Drug: Ustekinumab induction
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab induction dose
Study: 35509022
Drug: Magnetically controlled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetically controlled capsule endoscopy (MCE)
Study: 35509022
Drug: Magnetically controlled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetically controlled capsule endoscopy (MCE) with magnetic steering
Study: 35510711
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment (e.g., low-molecular-weight heparin)
Study: 35510711
Drug: No anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulation treatment
Study: 35511148
Drug: MRG003 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRG003 (0.1 to 2.5 mg/kg administered every 3 weeks during phase 1a; recommended dose of 2.5 mg/kg during phase 1b)
Study: 35511170
Drug: Appropriate medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate medical therapy
Study: 35511740
Drug: IMGC936 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMGC936 (a next-generation maytansinoid-based antibody-drug conjugate)
Study: 35511920
Drug: Orally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Study: 35511920
Drug: Intranasally delivered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine
Study: 35512229
Drug: Non-recommended edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-recommended edoxaban dose regimens
Study: 35512742
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) with adjuvant gemcitabine-based chemotherapy administered 8-12 weeks after surgery.
Study: 35512743
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment with VerifyNow assay results
Study: 35513751
Drug: One occurrence
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One occurrence of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Study: 35513751
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more occurrences of hyperchloremia (serum chloride levels ≥110 mmol/L) within 72 hours
Study: 35513826
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of LMWH (> 100 IU/kg/day)
Study: 35513826
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose of LMWH (≤ 100 IU/kg/day)
Study: 35513826
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose of LMWH
Study: 35514201
Drug: Eculizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (1200 mg IV on Day 1, additional doses of 1200 mg IV on Days 4 and 8; 900 mg IV on Days 15 and 22; optional doses on Days 12 and 18)
Study: 35514770
Drug: Treprostinil inhalation
Normalized name: treprostinil Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treprostinil inhalation powder (TreT)
Study: 35514770
Drug: Treprostinil inhalation
Normalized name: treprostinil Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treprostinil inhalation solution
Study: 35518121
Drug: Vibrating capsule
Normalized name: VIBRATING DEVICE,CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrating capsule (VC), two capsules per week for six weeks
Study: 35521657
Drug: Durvalumab (MEDI4736)
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab (MEDI4736) with Tremelimumab in combination with image-guided stereotactic body radiotherapy
Study: 35522941
Drug: PD-L1/TIGIT bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-L1/TIGIT bispecific antibody
Study: 35523118
Drug: Desmopressin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin administered IV
Study: 35524015
Drug: Patient-specific PEEK
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific PEEK implant
Study: 35524239
Drug: Alpelisib 350
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib 350 mg QD combined with Imatinib 400 mg QD
Study: 35525964
Drug: STOP (Self-regulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOP (Self-regulation Therapy for Opioid addiction and Pain)
Study: 35526096
Drug: ABL501 (LAG-3xPD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABL501 (LAG-3xPD-L1 bispecific antibody)
Study: 35526096
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PD-1/PD-L1 blockade with other checkpoint inhibitors
Study: 35526308
Drug: Regorafenib 80
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 80 mg and Nivolumab 240 mg every 2 weeks
Study: 35526554
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative treatment (982 patients)
Study: 35527353
Drug: Poor self-reported
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor self-reported oral health
Study: 35527798
Drug: Online Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Mindfulness-Based Cognitive Therapy (MBCT)
Study: 35529085
Drug: Finerenone (nonsteroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Study: 35530041
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment algorithm including non-steroidal anti-inflammatory drugs, corticosteroids, anticoagulants, oxygen therapy, and antibiotics.
Study: 35533265
Drug: Pre-meal and
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-meal and basal insulin omission
Study: 35533793
Drug: Amoxicillin (TDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (TDM with ≥1 intermediate and ≥1 trough level performed 24 h after therapy initiation)
Study: 35534083
Drug: Daily stress
Normalized name: Natrol Daily Stress Relief Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily stress
Study: 35534310
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine (Rotarix®)
Study: 35534690
Drug: Induction chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemo-immunotherapy (ICIT)
Study: 37314665
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept 125 mg once weekly
Study: 35536617
Drug: Biological age
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological age estimation model using 9 physiological biomarkers
Study: 35536669
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CSA) at a starting dose of 9 mg/kg/d
Study: 35537101
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years; Venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1
Study: 35537111
Drug: AKST4290 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKST4290 (400 mg) orally twice daily for 6 weeks
Study: 35537411
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor blockade
Study: 35537782
Drug: Camrelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily)
Study: 35538105
Drug: De-escalated adjuvant
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalated adjuvant antibody doublet therapy (trastuzumab and pertuzumab) without chemotherapy
Study: 35538502
Drug: Pharmacological and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological and non-pharmacological treatments
Study: 35538502
Drug: Speech and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech and language therapy (SLT)
Study: 35538512
Drug: NI-1701 (CD47xCD19
Approvals — FDA: no, EMA: no, PMDA: no
Description: NI-1701 (CD47xCD19 bispecific antibody)
Study: 35544727
Drug: First- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: First- or second-line systemic therapy for advanced/metastatic CCA
Study: 35544759
Drug: 1% chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chloroprocaine (40 mL)
Study: 35544759
Drug: 2% chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chloroprocaine (40 mL)
Study: 35544759
Drug: 3% chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% chloroprocaine (40 mL)
Study: 35545011
Drug: Anti-S100A8/A9 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-S100A8/A9 antibody
Study: 35545011
Drug: Flo1-2a anti-murine
Normalized name: Murine Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flo1-2a anti-murine anti-IL-1α monoclonal antibody
Study: 35545011
Drug: XB2001 (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: XB2001 (specific anti-human IL-1α antibody)
Study: 35545657
Drug: Self-managed lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-managed lifestyle treatment using a digital tool
Study: 35545778
Drug: Pevonedistat alone
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat alone or in combination with azacitidine
Study: 35546043
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg) for 8 weeks
Study: 35546396
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and stabilization occlusal splint
Study: 35546401
Drug: Pronolis®HD mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronolis®HD mono 2.5% (high-density sterile viscoelastic solution of hyaluronic acid)